Multi-modal skin atlas identifies a multicellular immune-stromal community associated with disrupted cornification and specific T cell expansion in atopic dermatitis
- PMID: 41741455
- DOI: 10.1038/s41467-026-69587-7
Multi-modal skin atlas identifies a multicellular immune-stromal community associated with disrupted cornification and specific T cell expansion in atopic dermatitis
Abstract
In atopic dermatitis (AD), skin barrier and immune dysfunction result in chronic tissue inflammation, yet our understanding of the tissue ecosystem remains incomplete. Here, we generate a multi-modal census of 280,518 cells from whole skin tissue samples from 17 adults, including 11 AD patients, integrating it with 430,186 cell profiles from four previous studies into a comprehensive human skin cell atlas. Reconstruction of keratinocyte differentiation revealed disrupted cornification in AD associated with signals from an immune and stromal multicellular community - comprising MMP12+ and migratory dendritic cells (DCs), cycling innate lymphoid cells (ILC), natural killer cells, inflammatory CCL19+ IL4I1+ fibroblasts, and clonally expanded IL13+IL22+IL26+ T cells connected by intercellular feedback loops predicted to impact community assembly. Subsets from this community, along with disrupted cornified keratinocytes, were enriched in GWAS, suggesting that dysfunction in this communication network may initiate AD. Our work highlights disease-associated cell subsets and interactions in chronic skin inflammation.
© 2026. The Author(s).
Conflict of interest statement
Competing interests: A.R. was a founder and equity holder of Celsius Therapeutics, is an equity holder in Immunitas Therapeutics, and until 31 July 2020 was an SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov, and ThermoFisher Scientific. From 1 August 2020, A.R. is an employee of Genentech, a member of the Roche Group, with equity in Roche. R.J.X. is a co-founder of Celsius Therapeutics, Jnana Therapeutics, and director of Moonlake Immunotherapeutics. R.J.X. is an SAB member of Magnet Biomedicine and of Nestlé. From 19 October 2020 to 4 April 2022, respectively, O.R.-R. and G.E. are employees of Genentech, a member of the Roche Group, and have equity in Roche. The remaining authors declare no competing interests.
Update of
-
Multi-modal skin atlas identifies a multicellular immune-stromal community associated with altered cornification and specific T cell expansion in atopic dermatitis.bioRxiv [Preprint]. 2023 Oct 31:2023.10.29.563503. doi: 10.1101/2023.10.29.563503. bioRxiv. 2023. Update in: Nat Commun. 2026 Feb 25. doi: 10.1038/s41467-026-69587-7. PMID: 37961084 Free PMC article. Updated. Preprint.
References
-
- Langan, S. M., Irvine, A. D. & Weidinger, S. Atopic dermatitis. Lancet 396, 345–360 (2020).
-
- Jungersted, J. M. et al. Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema. Allergy 65, 911–918 (2010).
-
- Sanyal, R. D. et al. Atopic dermatitis in African American patients is T2/T22-skewed with T1/T17 attenuation. Ann. Allergy Asthma Immunol. 122, 99–110.e6 (2019).
-
- Nettis, E. et al. Use of dupilumab in 543 adult patients with moderate-to-severe atopic dermatitis: a multicenter, retrospective study. J. Investig. Allergol. Clin. Immunol. 32, 124–132 (2022).
-
- Renert-Yuval, Y. & Guttman-Yassky, E. New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines. Ann. Allergy Asthma Immunol. 124, 28–35 (2020).
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
